“ALTUVIIIO’s treatment regimen and bleed protection has been good for me.”
A treatment change during a life change
I considered switching before, but I feared change. Plus, I was managing my hemophilia decently. My loved ones kept me on track. But that was before college. At school, there were changes in my environment that made frequent treatments harder. So that drew me to finally switch.
It takes a team
When I have a concern, I reach out to my care team immediately. So, during my switch to ALTUVIIIO, I knew they'd help me overcome my initial anxiety. I understood the benefits and potential risks, and I was able to switch more seamlessly than I was expecting.
Living more freely
ALTUVIIIO’s treatment regimen and bleed protection has been good for me. My factor levels stay higher for most of the week, and I have peace of mind about my level of protection. And with the once-weekly dosing regimen, I have the freedom to focus on the things I love.
A look at the numbers
I look at the PK curves in the context of PK curves on my prior treatment, and the value of ALTUVIIIO is clear to me. Between the time I started on it until now, the numbers have spoken for themselves. My Factor VIII levels stay higher for more days of the week. And the infusion process is incredibly similar to other medications I've used, so again, switching was not difficult.
Discussing a switch with patients
I’d encourage other doctors to present all the information to patients in a way that’s easy to understand. Convey the potential advantages of switching. Discuss any restrictions and potential side effects. And be transparent, especially given how skeptical some patients can be. They may think there’s a “catch,” but doctors can show them that there could be benefits to considering a new treatment option.
This testimonial reflects one patient’s experience and has not been clinically evaluated. It is not intended to imply typical outcomes or substitute for clinical evidence. Daniel is a promotional speaker compensated by Sanofi.
PK=pharmacokinetic.
